A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy
Publication
, Conference
Jotte, RM; Conkling, PR; Reynolds, C; Allen, AR; Oliver, JW
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2008
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
May 20, 2008
Volume
26
Issue
15
Publisher
AMER SOC CLINICAL ONCOLOGY
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Jotte, R. M., Conkling, P. R., Reynolds, C., Allen, A. R., & Oliver, J. W. (2008). A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 26). AMER SOC CLINICAL ONCOLOGY.
Jotte, R. M., P. R. Conkling, C. Reynolds, A. R. Allen, and J. W. Oliver. “A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 26. AMER SOC CLINICAL ONCOLOGY, 2008.
Jotte RM, Conkling PR, Reynolds C, Allen AR, Oliver JW. A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2008.
Jotte, R. M., et al. “A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy.” JOURNAL OF CLINICAL ONCOLOGY, vol. 26, no. 15, AMER SOC CLINICAL ONCOLOGY, 2008.
Jotte RM, Conkling PR, Reynolds C, Allen AR, Oliver JW. A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2008.
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
May 20, 2008
Volume
26
Issue
15
Publisher
AMER SOC CLINICAL ONCOLOGY
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences